New antibiotic is effective against gonorrhea, could be first new treatment since 1990s, study says
A new type of antibiotic for treatment of urinary tract infections in women could also work against gonorrhea infections, a new study finds. This could put the medication, called gepotidacin, on track to become the first new antibiotic for gonorrhea since the 1990s.
'Gepotidacin is a novel oral antibacterial treatment with the potential to become an alternative option for the treatment of gonococcal infections, supported by an acceptable safety and tolerability profile,' the researchers wrote in the study published Monday in The Lancet, adding that the drug 'could mark a meaningful advancement in patient care.'
As an antibiotic, gepotidacin works by inhibiting bacteria from replicating in the body. In March, it was approved by the US Food and Drug Administration to treat uncomplicated urinary tract infections in women and girls ages 12 and older. Recurrent UTIs have become a bigger problem as the bacteria that cause them have become more resistant to the antibiotics available to treat them.
Now, there is new hope that gepotidacin may help fight drug-resistant gonorrhea.
'The big takeaway is that having additional treatment options for gonorrhea is fantastic,' said Dr. Jason Zucker, an infectious disease and sexually transmitted infections expert and assistant professor of medicine at Columbia University Vagelos College of Physicians and Surgeons, who was not involved in the new study.
Effective treatments for gonorrhea have become increasingly limited in recent years due to the global rise of antimicrobial resistance in Neisseria gonorrhoeae, the bacteria that cause gonorrhea, rendering many previously used first-line antibiotics ineffective.
The current standard of care involves an intramuscular injection of the antibiotic ceftriaxone, which requires a visit to a care facility.
A key benefit of gepotidacin is that it would not involve an injection at the doctor's office, which could make treating gonorrhea more convenient for patients, Zucker said.
'Right now, patients come in, especially if they are not having symptoms, if they test positive, we have to ask them to come back. For some people, that's not so easy,' he said. 'So obviously, the ability to have the pharmacy send treatment to their house, or have them be able to pick it up, would really make things a lot easier for people and reduce the number of doctor visits they have, especially if they have jobs where they don't have a lot of time off.'
Gonorrhea can lead to serious health problems if left untreated, and though rare, can even spread to the blood or joints. Among women, untreated gonorrhea can cause an infection of the reproductive organs called pelvic inflammatory disease, which can lead to a greater risk of pregnancy complications and infertility. In men, gonorrhea also can lead to infertility in rare cases.
In the United States, gonorrhea and other sexually transmitted infections or STIs have become more common. Reported cases of three nationally notifiable STIs – chlamydia, gonorrhea and syphilis – were up 90% in the US in 2023 compared with about two decades prior in 2004, according to data released last year by the US Centers for Disease Control and Prevention. More than 2.4 million cases of STIs were reported in 2023 nationally.
The Phase 3 trial, conducted between October 2019 and October 2023, included more than 600 people ages 12 and older who were diagnosed with gonorrhea in the urogenital area across six countries: Australia, Germany, Mexico, Spain, the United Kingdom and the United States.
The study was funded by the pharmaceutical company GSK, which developed the antibiotic, and the development of gepotidacin was funded in part with federal funds from the US Department of Health and Human Services, Administration for Strategic Preparedness and Response, Biomedical Advanced Research and Development Authority, and the Defense Threat Reduction Agency, according to GSK.
About half of the study participants were treated with a gepotidacin regimen of two oral doses administered about 10 to 12 hours apart, at 3,000-milligrams per dose. The other participants were provided with the current standard treatment of administering a single dose of the antibiotic ceftriaxone as an injection paired with orally taking the antibiotic azithromycin.
The trial data, which is being presented at the European Society of Clinical Microbiology and Infectious Diseases conference, showed that gepotidacin was as effective as the current leading combination treatment, and was also effective against treatment-resistant infections, which occur when strains of gonorrhea are resistant to currently used antibiotics.
The gonorrhea infections were cured among 92.6% of the study participants who were administered gepotidacin compared with 91.2% of the study participants who were treated with ceftriaxone plus azithromycin.
Among the 7.4% of participants in the gepotidacin group who were not successfully treated, they all were due to missing data, according to GSK, which added that 'in participants with complete data, there was no bacterial persistence at the urogenital body site.'
While the study primarily assessed gepotidacin as a treatment for urogenital gonorrhea, some participants with rectal and throat infections were evaluated. Of those with complete data, the study showed that it was more difficult to treat gonorrhea in the throat compared with other body sites, as 14 out of 16 people with throat gonorrhea and complete data – 88% – were successfully treated.
The researchers wrote that the prevalence of throat infections 'warrants further investigation' in a larger group of participants, as does studying the efficacy of geptodiacin in the treatment of gonorrhea in the throat.
'Pharyngeal gonorrhea is notoriously harder to treat and plays a key role in silent transmission and resistance development, so having reliable oral options at all anatomical sites is critical,' Zucker, said.
The international team of researchers found no life-threatening nor fatal side effects associated with either treatment approach used in the study, but the gepotidacin group had higher rates of side effects compared with the ceftriaxone-plus-azithromycin group, which were mostly gastrointestinal, such as diarrhea and nausea, and almost all were mild or moderate, according to the study.
'One of the challenges is that a lot of oral antibiotics have GI side effects,' Zucker said.
The researchers noted that it will be important to investigate the efficacy of gepotidacin for treating gonorrhea in groups not primarily represented in the study especially women and Black and Brown communities, as 92% of participants in the study were men, 74% were White and 71% were men who have sex with men.
If gepotidacin is approved for the treatment of gonorrhea in the United States, 'the price will be disclosed when the product will be supplied in a market. Our approach would be for it to reflect the value and outcomes they bring to patients, providers and payers while being sensitive to market and societal expectations,' according to a GSK spokesperson.
Bluejepa, the brand name for the version of gepotidacin approved in the United States to treat UTIs, is expected to be available in the second half of 2025.
The new study was 'very well-done' with 'rigorous data,' and having more options to treat gonorrhea is critical for slowing down the bacteria's drug resistance, said Dr. Jeffrey Klausner, a clinical professor of public health at the University of Southern California's Keck School of Medicine in Los Angeles, who was not involved in the trial.
'The more options doctors have to treat gonorrhea means that they do not have to use the same drug over and over again, which is a recipe for disaster and more resistance. We know that using the same drug over and over again leads to drug resistance,' Klausner said in the email. 'If gepotidacin is approved and recommended for gonorrhea treatment, that is a true advance and will greatly help our efforts to slow down drug resistance in gonorrhea.'
In the study, researchers noted that using gepotidacin to treat gonorrhea as an oral treatment option, not an injection, may be more efficient and reduces the risk of persistent, drug-resistant infections.
Yet there is some concern that strains of gonorrhea may eventually develop resistance to gepotidacin, according to a comment paper accompanying the new study in The Lancet.
'In our opinion, N gonorrhoeae will also develop gepotidacin resistance when the selective pressure increases and where compliance to the dual-dose regimen is suboptimal,' Magnus Unemo of Örebro University in Sweden and Teodora Wi of the World Health Organization in Switzerland wrote in the paper.
'Due to the inherent ability of gonococci to develop resistance, difficulties in increasing the gepotidacin dose due to adverse events, and the lack of other treatment options, preclinical and clinical development of additional gonorrhoea treatments remains important,' they wrote. 'In conclusion, gepotidacin is promising for the treatment of gonorrhoea, but the challenges to retain gonorrhoea as a treatable infection will continue.'
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a day ago
- Yahoo
Newly approved therapy could offer another option for protecting infants from RSV, a common infection that can be deadly
The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that's the No. 1 cause of hospitalization in infants. The US Food and Drug Administration has approved a new monoclonal antibody to help prevent infection, according to an announcement late Monday from drugmaker Merck. The therapy, Enflonsia, is designed to be given in a single 105-milligram shot to protect newborns and infants from mild, moderate or severe RSV through all five months of their first virus season, which typically starts in the fall and goes through the next spring. Study materials that Merck submitted to the FDA for its approval showed that the antibody had a similar safety profile as a placebo. The most common adverse reactions from Enflonsia were mild and included injection-site swelling and a rash in a small number of infants. In a mid- to late-stage trial, Enflonsia reduced RSV-associated hospitalizations in infants more than 84% compared with a placebo. RSV can sometimes turn into serious lower respiratory infections like pneumonia, but the shot also reduced lower respiratory infections that needed medical attention by more than 60% compared with a placebo. 'Enflonsia provides an important new preventive option to help protect healthy and at-risk infants born during or entering their first RSV season,' Dr. Dean Y. Li, president of Merck Research Laboratories, said in a news release. 'We are committed to ensuring availability of Enflonsia in the US before the start of the upcoming RSV season to help reduce the significant burden of this widespread seasonal infection on families and health care systems.' Merck says it hopes Enflonsia will be available before the start of the 2025-26 respiratory virus season. First, it needs to be recommended by the US Centers for Disease Control and Prevention, and that means going in front of the agency's Advisory Committee on Immunization Practices. It's on the agenda for the panel's meeting this month, but US Health and Human Services Secretary Robert F. Kennedy removed all the members of that committee Monday. He says he will appoint new ones, but it's unclear how long that process will take. Doctors say another tool to prevent RSV cannot come soon enough. RSV is ubiquitous, one of the most common causes of childhood illness. Most kids will catch this highly contagious respiratory virus at some point before they turn 2, according to the CDC. For many healthy adults and older kids, RSV causes a mild illness like a cold. Typically, symptoms can be managed at home, and they often go away on their own. But for infants and the elderly, it can be a different story. Very young children's immune systems are just starting to learn how to fight infections, and infants have tiny airways. RSV inflames those airways, making it difficult to breathe, and can turn into a serious lower respiratory illness like bronchiolitis or pneumonia. Some of these RSV infections can be deadly. Two to three percent of infants under 6 months are hospitalized with RSV in the US every year, according to the CDC. Among children younger than 5, about 58,000 to 80,000 are hospitalized due to RSV. There's no specific medicine to treat RSV. Doctors can give an infant supportive care and oxygen, and then they essentially wait until their oxygen levels get back to normal, said Dr. Amy Edwards, director of pediatric infection control at UH Rainbow Babies and Children's Hospital in Cleveland. 'I hate RSV,' said Edwards, who was not connected with the Merck trial. 'Just to watch them struggle to breathe, and then they get scared, and then they cry, which of course makes the breathing worse, and their little lips turn blue. It's just so hard to watch.' Enflonsia joins a handful of other tools recently made available to protect babies from, although the FDA put RSV vaccine trials involving infants and young children ages 2 to 5 on hold last year after some developed severe illness. To prevent RSV in infants, the CDC currently recommends an RSV antibody made by Sanofi and AstraZeneca, called Beyfortus, which was approved in 2023. It was in short supply during that year's RSV season, although Edwards said supply started to catch up with demand in her health care system last season, and the company pledged to produce more. The other option to protect an infant is a vaccine that a person can get during pregnancy. Together, Beyfortus and the vaccine have made a difference. A CDC study published in March found that RSV-associated hospitalization rates among infants up to 7 months during 2024-25 season were lower than in seasons when those therapies weren't available. Edwards just hopes people will get protection for their infants. 'Every RSV season fills us to the gills,' she said. 'This should theoretically empty us out, if we have good uptake.'
Yahoo
a day ago
- Yahoo
Innoviva Specialty Therapeutics Receives FDA New Drug Application Acceptance for Zoliflodacin, a First-in-Class Oral Antibiotic for Uncomplicated Gonorrhea in Adults
In laboratory studies, zoliflodacin has been shown to be active against Neisseria gonorrhoeae including multidrug-resistant strains. If approved, zoliflodacin could become the first new antibiotic treatment for gonorrhea in decades. WALTHAM, Mass. & GENEVA, Switzerland, June 10, 2025--(BUSINESS WIRE)--Innoviva Specialty Therapeutics, Inc., a subsidiary of Innoviva, Inc. (NASDAQ: INVA), in collaboration with the Global Antibiotic Research & Development Partnership (GARDP), today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for zoliflodacin, the investigational first-in-class, single dose, spiropyrimidinetrione oral antibiotic for the treatment of uncomplicated gonorrhea in adults and pediatric patients 12 years and older. If approved, zoliflodacin would be the first new antibiotic for treating gonorrhea in decades. With more than 82 million new gonorrhea infections occurring globally each year, gonorrhea is the second most common bacterial sexually transmitted infection (STI), affecting both men and women, which, if left untreated, can result in serious and permanent health consequences. With the rise and spread of drug-resistant infections and the World Health Organization (WHO) identifying antimicrobial resistance (AMR) as one of the ten most critical global threats to public health, the bacterium Neisseria gonorrhoeae has progressively developed resistance to many classes of antibiotics used to treat these infections, including ceftriaxone, a widely used intramuscular injection that was first made available in 1984. "Today's acceptance of the zoliflodacin NDA marks significant progress toward delivering health care providers with a potential new oral treatment option for uncomplicated gonorrhea, including infections caused by drug-resistant strains," said David Altarac, M.D., Chief Medical Officer, Innoviva Specialty Therapeutics. "We look forward to working closely with the FDA during its review and, if approved, we are committed to expediting the availability of zoliflodacin to patients in the U.S." Recent reports (The Lancet Infectious Diseases) of emergent ceftriaxone-resistant infections have heightened the urgency for new antibiotics. Effective treatment options are essential to reducing the burden of disease for individuals and preventing the spread of highly drug-resistant gonorrhea globally. If left untreated, gonorrhea can also cause infertility in women, life-threatening ectopic pregnancies, and pelvic inflammatory disease.2 The FDA's acceptance of the zoliflodacin NDA is based on the totality of data collected from several clinical trials as part of an innovative public-private partnership with GARDP. These trials include a pivotal Phase 3 clinical trial which demonstrated non-inferiority in achieving microbiological cure at the urogenital site of infection of a single oral dose of zoliflodacin compared to a treatment regimen of a single intramuscular injection of ceftriaxone followed by 1 week of oral azithromycin. The Phase 3 study found that zoliflodacin was generally well-tolerated, with no serious adverse events or deaths reported during the trial. "This important milestone demonstrates the crucial role that public-private partnerships can play in tackling the escalating global antimicrobial resistance crisis," said Dr. Manica Balasegaram, Executive Director, Global Antibiotic Research Development Partnership (GARDP). "If zoliflodacin is approved, this collaboration paves the way for millions of people across the world to get access to a potentially powerful new drug to treat multidrug-resistant gonorrhea." Zoliflodacin has a unique mechanism of action, inhibiting a crucial bacterial enzyme called type II topoisomerase, which is essential for bacterial function and reproduction. In vitro studies have demonstrated its activity against multidrug-resistant strains of Neisseria gonorrhoeae, including those resistant to ceftriaxone and azithromycin, with no cross-resistance to other antibiotics. This investigational antibacterial is administered in a single, oral dose, simplifying treatment by providing a convenient option for patients unable to receive an intramuscular injection. The U.S. FDA has granted zoliflodacin a Qualified Infectious Disease Product (QIDP) designation. This designation allows it to benefit from FDA Priority Review, and Extended Market Exclusivity. Innoviva Specialty Therapeutics, Inc., anticipates that the NDA review will proceed according to the standard process for drugs with this designation. Entasis Therapeutics, Inc., the legal NDA holder and affiliate of Innoviva Specialty Therapeutics, Inc., retains the commercial rights for zoliflodacin in the major markets in North America, Europe, and Asia-Pacific. GARDP retains the right to register and commercialize the product in more than three-quarters of the world's countries, including all low-income countries, most middle-income countries, and several high-income countries. GARDP is committed to working with its partners and local health authorities in markets where zoliflodacin receives regulatory approval to help remove access barriers to ensure treatment is available to address unmet medical needs while ensuring appropriate and sustainable use. About GARDP The Global Antibiotic Research & Development Partnership (GARDP) is a not-for-profit global health organization driven to protect people from the rise and spread of drug-resistant infections, one of the biggest threats to us all. By forging the public and private partnerships that matter, we develop and make accessible antibiotic treatments for people who need them. Vital support for our work comes from the governments of Canada, Germany, Japan, Monaco, the Netherlands, Switzerland, the United Kingdom, the Canton of Geneva, the European Union, as well as the Gates Foundation, Global Health EDCTP3, GSK, the RIGHT Foundation, the South African Medical Research Council (SAMRC) and Wellcome. About Innoviva Innoviva is a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ("IST"), and a portfolio of strategic investments in healthcare assets. Innoviva's royalty portfolio includes respiratory assets partnered with Glaxo Group Limited ("GSK"). Innoviva is entitled to receive royalties from GSK on sales of RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®. Innoviva's other innovative healthcare assets include infectious disease and critical care assets stemming from acquisitions of Entasis Therapeutics, including XACDURO® (sulbactam for injection; durlobactam for injection), co-packaged for intravenous use approved for the treatment of adults with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible strains of Acinetobacter baumannii-calcoaceticus complex and the investigational zoliflodacin currently being developed for the treatment of uncomplicated gonorrhea, and La Jolla Pharmaceutical Company, including GIAPREZA® (angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock and XERAVA® (eravacycline) for the treatment of complicated intra-abdominal infections in adults. On December 14, 2024, Innoviva entered into an exclusive distribution and license agreement with Basilea Pharmaceutica Ltd, Allschwil for the commercialization of ZEVTERA® (ceftobiprole), an advanced-generation cephalosporin antibiotic, in the U.S. For more information about Innoviva, go to For information about Innoviva Specialty Therapeutics, go to View source version on Contacts Media Contacts:Innoviva Specialty TherapeuticsDavid +1.908.421.5971GARDPDuncan Graham-Rowedgrahamrowe@ +44 7966 413623 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Yahoo
a day ago
- Yahoo
A quarter of the world's population are adolescents: major report sets out health and wellbeing trends
The Lancet has released its second global commission report on Adolescent Health and Wellbeing. Adolescents are defined as 10- to 24-year-olds. The report builds on the first one, done in 2016. The latest report presents substantial original research that supports actions it recommends to be taken across sectors as well as at global, regional, country and local level. The co-chairs of the commission, Sarah Baird, Alex Ezeh and Russell Viner, together with the youth commissioners lead, Shakira Choonara, give a guide to the report's findings. The report noted significant improvements in some aspects of adolescent health and wellbeing since the 2016 report. These include reductions in: communicable, maternal and nutritional diseases, particularly among female adolescents the burden of disease from injuries substance use, specifically tobacco and alcohol teenage pregnancy. It also found that there had been an increase in age at first marriage and in education, especially for young women. Despite this progress, adolescent health and wellbeing is said to be at a tipping point. Continued progress is being undermined by rapidly escalating rates of non-communicable diseases and mental disorders, accompanied by threats from compounding and intersecting megatrends. These include climate change and environmental degradation, the growing power of commercial influences on health, rising conflict and displacement, rapid urbanisation, and the aftermath of the COVID-19 pandemic. These megatrends are outpacing responses from national governments and the international community. Born between 2000 and 2014, this is the first cohort of humans who will live their entire life in a time when the average annual global temperature has consistently been 0.5°C or higher above pre-industrial levels. At roughly 2 billion adolescents, they are the largest cohort of adolescents in the history of humanity. And this number will not be surpassed as populations age and fertility rates fall in even the poorest countries. They are the first generation of global digital natives. They live in a world of immense resources and opportunities, with unprecedented connectedness made possible by the rapid expansion of digital technologies. This is true even in the hardest-to-reach places. Growing participation in secondary and tertiary education is equipping adolescents of all genders with new economic opportunities and providing pathways out of poverty. These opportunities, however, are not being realised for most adolescents. Increasing numbers continue to grow up in settings with limited opportunities. In addition, investments in adolescent health and wellbeing continue to lag relative to their population share or their share of the global burden of disease. Investments in adolescents accounted for only 2.4% of the total development assistance for health in 2016-2021. This was despite the fact that adolescents accounted for 25.2% of the global population in that period and 9.1% of the total burden of disease. We use development assistance as a measure because, while governments also invest in adolescents, it's difficult to account for how much this is. For example, when a government supports a health facility, it serves the entire population. Yet, the report provides evidence to show that the return on investments in adolescent health and wellbeing is highly cost-effective and at par with investments in children. The report recognises the special place of Africa in the global future of adolescents. It notes that, by the end of this century, nearly half of all adolescents will live in Africa. Currently, adolescents in Africa experience higher burdens of communicable, maternal and nutritional diseases, at more than double the global average for both male and female adolescents. They also have a higher prevalence of anaemia, adolescent childbearing, early marriage and HIV infection. They are much less likely to complete 12 years of schooling and more likely to not be in education, employment, or training. Female adolescents in sub-Saharan Africa have the highest adolescent fertility rate at 99.4 births per 1,000 female adolescents aged 15-19 (the global average is 41.8). They have also experienced the slowest decline between 2016 and 2022. Globally, there was progress in reducing child marriage between 2016 and 2022. But in eight countries in 2022, at least one in three female adolescents aged 15–19 years was married. All but one of these eight countries were in sub-Saharan Africa. Niger (50.2%) and Mali (40.6%) had the highest proportion of married female adolescents. The practice of child marriage is declining in south Asia and becoming more concentrated in sub-Saharan Africa. As the report notes: it continues because of cultural norms, fuelled by economic hardships, insurgency, conflict, ambiguous legal provisions, and lack of political will to enforce legal provisions. Beyond adolescent sexual and reproductive health concerns in sub-Saharan Africa, obesity is increasing fastest in the region. This illustrates the vulnerability of adolescents to the power of commercial interests. Since 1990, obesity and overweight has increased by 89% in prevalence among adolescents aged 15–19 years in sub-Saharan Africa. This is the largest regional increase. The absence of data on adolescents is a problem. Adolescents in sub-Saharan Africa are absent in many data systems. For example, data on adolescent mental health in sub-Saharan Africa is virtually absent. Stronger data systems are needed to understand and track progress on the complex set of determinants of adolescent health and wellbeing. Another area of concern is the massive inequities within countries, often gendered or by geography. While female adolescents in Kenya are experiencing substantial declines in the burden of HIV and sexually transmitted infections, adolescent males are experiencing increasing burdens. In South Africa, years of healthy life lost to maternal disorders show more than 10-fold differences between the Western Cape and North West provinces. Where there's been strong political leadership, remarkable changes have been seen. Take the case of Benin Republic. The adolescent fertility rate in the country declined from 26% in 1996 to 20% in 2018 and child marriage from 39% to 31% over the same period. Strong political leadership has also led to substantial reductions in female genital mutilation or cutting. This fell from 12% of girls in Benin in 2001 to 2% in 2011–12 among 15–19-year-old girls in Benin Republic. Political leadership also facilitated the expansion, by the national parliament in 2021, of the grounds under which women, girls, and their families could access safe and legal abortion. But for every country that takes positive steps to protect the health and wellbeing of adolescents, several others regress. The last decade has witnessed regression in several countries. In 2024, The Gambia attempted to repeal a 2015 law criminalising all acts of female genital mutilation or cutting. In 2022, Nigeria's federal government ordered the removal of sex education from the basic education curriculum. The report calls for a multisectoral approach across multiple national ministries and agencies, including the office of the head of state, and within the UN system. Coordination and accountability mechanisms for adolescent health and wellbeing also need to be strengthened. Laws and policies are needed to protect the health and rights of adolescents, reduce the impact of the commercial determinants of health, and promote healthy use of digital and social media spaces and platforms. Strong political leadership at local, national, and global levels is essential. The report also calls for prioritised investments, the creation of enabling environments to transform adolescent health and wellbeing, and the development of innovative approaches to address complex and emerging health threats. It calls for meaningful engagement of adolescents in policy, research, interventions and accountability mechanisms that affect them. Without these concerted actions, we risk failing our young people and losing out on the investments being made in childhood at this second critical period in their development. The current adverse international aid climate is particularly affecting adolescents as much development assistance relates to gender and sexual and reproductive health. Concerted action in addressing adolescent health and wellbeing is an urgent imperative for sub-Saharan Africa. This article is republished from The Conversation, a nonprofit, independent news organization bringing you facts and trustworthy analysis to help you make sense of our complex world. It was written by: Alex Ezeh, Drexel University; Russell Viner, UCL, and Sarah Baird, George Washington University Read more: Canada must take action to prevent climate-related migration We design cities and buildings for earthquakes and floods — we need to do the same for wildfires Eating wild meat carries serious health risks – why it still happens along the Kenya-Tanzania border Alex Ezeh is a fellow at the Stellenbosch Institute for Advanced Study (Stias). Russell Viner and Sarah Baird do not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and have disclosed no relevant affiliations beyond their academic appointment.